Il Tempo

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres

- WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of ...
Pharm Exec

FDA Approves Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...
Finanznachrichten

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres Y-90 resin microspheres

Physicians and employees recognized for their role in this milestone and impact made on patient lives WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of ...